High Remission Rate in Acute Myeloblastic Leukemia with Only Two Days of Chemotherapy

References

• Rai K R, Holland J F, Glidewell O J, Weinberg V, Brunner K, Obrecht J P, Preisler. Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B. Blood 1981; 58: 1203–1212
   PubMed Web of Science ®Google Scholar
• Cassileth P A, Lynch E, Mines J D, Oken M M, Mazza J J, Bennett J M, McGlave P B, Edelstein M, Harrington D P, O'Connell M J. Varying intensity of post remission therapy in acute myeloid leukemia. Blood 1992; 79(8)1924–1930
   PubMed Web of Science ®Google Scholar
• Rees J KH, Gray R G, Swirsky D, Hayhoe F GJ. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial;. Lancet November, 1986; 29: 1236–1241
   Google Scholar
• Weick J K, Kopecky K J, Appelbaum F R, Head D R, Kingsbury L L, Balcerzak S P, Bickers J N, Hynes H E, Welborn J L, Simon S R, Grever M. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group Study. Blood 1996; 88(8)2841–2851
   PubMed Web of Science ®Google Scholar
• Dillman R O, Davis R B, Green M R, Weiss R B, Gottlieb A J, Caplan S, Kopel S, Preisler H D, McLntyre R O, Schiffner C. A comparative study of two different doses of Ara-C for acute myelocytic leukemia A phase III trial of Cancer and Leukemia Group B:. Blood 1991; 78(10)2520–2526
   PubMed Web of Science ®Google Scholar
• Preisler H D, David R B, Kirshner J, DuPre E, Richards F, Hoagland H C, Kopel S, Levy R N, Carey R, Schulman P, Gottlieb A, McLntyre O R. Comparison of three remission induction regimens and the two post-induction strategies for the treatment of ANLL. A CALGB Study, Blood 1987; 69(5)1441–1449
   PubMed Web of Science ®Google Scholar
• Yates J, Glidewell O, Wiernik P, Cooper M R, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchinson J L, Raich P, Nissen N, Eloison R R, Frelick R, James G W, Falkson G, Silver R T, Haurani F, Green M, Henderson E, Leone L, Holland J F. Cytosine arabinsoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: A CALGB study. Blood 1982; 60(2)454–462
   PubMed Web of Science ®Google Scholar
• Preisler H D, Venugopal P, Gregory S A, Hsu W -T, Loew J, Adler S, Gezer S, Creech S, Galvez A, Slivnick D, Andric T, Larson R A, Jejeh A. Poor prognosis acute myelogenous leukemia: 1-Response to treatment with high dose cyarabine/mitoxantrone/ethyol@(amifostine). Leuk Res 2000; 24(8)671–680
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Gallon D A, Gralnick H R, Sultan C. Proposals for the classification of the acute leukaemias. Br J Haemtaol 1976; 33(4)451–458
   PubMed Web of Science ®Google Scholar
• Anderlini P, Luna M, Kantarjian H M, O'Brien S, Pierce S, Keating M J. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 1996; 10(4)600–608
   PubMed Web of Science ®Google Scholar
• Preisler H D. Treatment failure in AML. Blood Cells 1982; 8: 585–602
   PubMedGoogle Scholar
• Taylor C Q, Dalton W S, Parrish P R, Gleason M C, Bellamy W T, Thompson F H, Roe D J, Trent J M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br. J Cancer 1991; 63: 923–929
   PubMed Web of Science ®Google Scholar
• Sato H, Preisler H D, Day R, Raza A, Larson R, Browman G, Goldberg J, Vogler R, Grunwald H, Gottlieb A, Bennett J, Gottesman M, Pastan I. MDR, transcript levels as an indication of resistant disease in acute nonlymphocytic leukemia:. Br J Haematol 1990; 75(7)340–345
   PubMed Web of Science ®Google Scholar
• Marie J P, Zittoun R, Sikic B I. Multidrug resistance (mdrl) gene expression in adult acute leukemias: Correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78(3)586–592
   PubMed Web of Science ®Google Scholar
• Preisler H D, Larson R A, Raza A, Browman G, Goldberg J, Vogler R, Day R, Gottlieb A, Vardiman J W, Bennett J, Kukla C, Grunwald H. The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukemia; Response to treatment and treatment failure. Br J Haematol 1991; 79: 390–397
   PubMed Web of Science ®Google Scholar
• Preisler H D, Raza A, Larson R, Goldberg J, Tricot G, Carey M, Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leuk Res 1992; 15(9)773–780
   Web of Science ®Google Scholar
• Preisler H D, Raza A. Current problems in the treatment of acute myelocytic leukemia (AML) and some possible solutions. Leukemia 1992; 6(2)81–84
   PubMedGoogle Scholar
• Glover D, Glick J H, Weiler C, Hurowitz S, Kligerman M M. WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Onc 1986; 4: 584–588
   PubMed Web of Science ®Google Scholar
• List A F, Heaton R, Glinsmann-Gibson B, Capizzi R L. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity. Semin Oncol 1996; 23(4)58–63
   PubMed Web of Science ®Google Scholar
• Gao X -Z, Chopra H K, Huang X -K, Preisler H D. The effects of amifostine (AM) on myelodysplasic and myeloid leukemia progenitor cells. Proc Amer Assoc Cancer Res 1997; 38: 323, Abst#2164
   Google Scholar
• Preisler H D, Bjornsson S, Henderson E S, Hyrniuk W, Higby D. Remission induction in acute non lymphocytic leukemia; Comparison of a 7-Day and 10-Day infusion of cytosine arabinoside in combination with adriamycin. Med Pediatr Onc 1979; 7: 269–275
   PubMedGoogle Scholar
• Preisler H D, Priore R, Azarnia N, Barcos M, Raza A, Vogler R, Browman G, Goldberg J, Grunwald H, Miller K, Brennan J, Chervenick P, Tricot G. Prediction of response of patients with acute non-lymphocytic leukemia to remission induction therapy: Use of clinical measurements. Br J Haematol 1986; 63(4)625–636
   PubMed Web of Science ®Google Scholar
• Benger A, Browman G, Walker I, Preisler H D, Goldberg J. Clinical evidence of accumulative effect of high dose cytarabine on the cerebellum in patients with acute leukemia: A Leukemia Intergroup Report. Cancer Treat Rep 1985; 69(2)240–241
   PubMedGoogle Scholar
• Mitus A J, Miller K B, Schenkein D P, Ryan H F, Parsons S K, Wheeler C, Antin J H. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13(7)1829–1830
   PubMedGoogle Scholar